logo
Plus   Neg
Share
Email
Comment

BioSante Pharma Reveals Positive Results Of Its Prostate Cancer Vaccine Study

Specialty pharmaceutical company BioSante Pharmaceuticals Inc (BPAX) Monday announced that the latest issue of The Lancet Oncology published the results from a Phase I dose escalation clinical study of GVAX Prostate cancer vaccine.

The results revealed that the GVAX Prostate cancer vaccine, used in treating metastatic castration-resistant prostate cancer patients in combination with ipilimumab, resulted in 53 percent of patients achieving at least stable disease, with two patients showing clear regression of metastases.

The results further revealed that 23 percent of patients in the higher dose cohorts had confirmed partial PSA response of greater than 50 percent from baseline.

The study further concluded that there were no serious adverse events in the lower dose Ipi cohorts and administration of immunotherapy was well tolerated and safe.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Tech giants Amazon.com, YouTube and Twitter as well as Verizon Communications are exploring bids for digital streaming rights to the National Football League or NFL's Thursday Night Football package, according to media reports. The NFL is likely to strike a multi-year deal for the digital streaming rights. However, the television audience for the NFL has declined for two consecutive years. Wynn Resorts Ltd. said Friday that former Chief Executive Officer Steve Wynn is not entitled to any severance payment of other compensation from the company. Wynn resigned last week as CEO and Chairman of the board following allegations of sexual misconduct. In a regulatory filing, Wynn Resorts said it entered into a separation agreement between Steve Wynn, and Wynn Resorts Holdings LLC. Beverages giant Coca-Cola Company on Friday reported a net loss for the fourth quarter, reflecting a one-time charge related to the U.S. tax reform and a double-digit decline in revenues. However, adjusted earnings per share matched analysts' expectations, while revenues beat their estimates. The company's shares are rising more than 2 percent in pre-market activity.
comments powered by Disqus
Follow RTT